Semaglutide 5mg
Semaglutide is a GLP-1 receptor agonist, which means it works by decreasing appetite in research subjects.
Semaglutide 10mg
Semaglutide 10mg
Semaglutide is a GLP-1 receptor agonist, which means it works by mimicking the incretin hormones in the body that regulate insulin secretion and appetite in research studies carried out so far.
Package 3 Semaglutide 5mg
Semaglutide is a GLP-1 receptor agonist, which means it works by decreasing appetite in research subjects.
Package 3 Semaglutide 10mg
Semaglutide 10mg
Semaglutide is a GLP-1 receptor agonist, which means it works by mimicking the incretin hormones in the body that regulate insulin secretion and appetite in research studies carried out so far.
Tirzepatide 5mg
Studies have shown significant weight reduction in subjects treated with Tirzepatide, making it a promising agent for obesity.
Tirzepatide 10mg
Studies have shown significant weight reduction in subjects treated with Tirzepatide, making it a promising agent for obesity.
Tirzepatide 15mg
Tirzepatide 15mg
Tirzepatide, a novel research treatment of type 2 diabetes and obesity, represents a significant advancement in pharmacotherapy. It’s a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism of action sets it apart from other antidiabetic drugs.
Package 3 Vials Tirzepatide 5mg
Studies have shown significant weight reduction in subjects treated with Tirzepatide, making it a promising agent for obesity.
Package 3 Vials Tirzepatide 10mg
Studies have shown significant weight reduction in subjects treated with Tirzepatide, making it a promising agent for obesity.
Retatrutide 6mg
Retatrutide has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity
Retatrutide 12mg
Retatrutide has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity
Package 3 Retatrutide 6mg
Retatrutide has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity
Package 3 Vials Retatrutide 12mg
Retatrutide has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity
MOTS-C 10mg
MOTS-C has gained attention in scientific research due to its potential benefits in metabolism, weight management, and disease prevention
Tirzepatide 30mg
Studies have shown significant weight reduction in subjects treated with Tirzepatide, making it a promising agent for obesity.
BAM-15 30ml
The primary interest in BAM-15 within bodybuilding circles is its potential to enhance fat loss by increasing metabolic rate.